LOMAIRA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lomaira, and what generic alternatives are available?
Lomaira is a drug marketed by Avanthi Inc and is included in one NDA.
The generic ingredient in LOMAIRA is phentermine hydrochloride. There are seventeen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the phentermine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lomaira
A generic version of LOMAIRA was approved as phentermine hydrochloride by ELITE LABS INC on May 30th, 1997.
Summary for LOMAIRA
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 44 |
Clinical Trials: | 4 |
Patent Applications: | 909 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for LOMAIRA |
DailyMed Link: | LOMAIRA at DailyMed |
Recent Clinical Trials for LOMAIRA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
The University of Texas Health Science Center, Houston | Phase 4 |
Kaiser Permanente | Phase 4 |
Biomedical Research Institute of New Mexico | Phase 4 |
Pharmacology for LOMAIRA
Drug Class | Sympathomimetic Amine Anorectic |
Physiological Effect | Appetite Suppression Increased Sympathetic Activity |
Anatomical Therapeutic Chemical (ATC) Classes for LOMAIRA
US Patents and Regulatory Information for LOMAIRA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Avanthi Inc | LOMAIRA | phentermine hydrochloride | TABLET;ORAL | 203495-001 | Sep 12, 2016 | AA | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |